Response to DLT for recurrent AML/MDS after BMT: EBMT-95 Survey
Treatment . | No. patients in CR/patients studied . | Survival time, d . |
|---|---|---|
| No chemotherapy | 9/36 | 112+, 155+, 291, 439, 503, 598+, 1007, 1014+, 2374 |
| Chemotherapy with CR | 14/15 | 60, 96, 159, 312+, 372+, 438+, 527, 646, 1173, 1245, 1416+, 1453+, 1463+, 1563+ |
| Chemotherapy without CR | 6/22 | 152, 617+, 800, 977, 1234+, 1263+ |
Treatment . | No. patients in CR/patients studied . | Survival time, d . |
|---|---|---|
| No chemotherapy | 9/36 | 112+, 155+, 291, 439, 503, 598+, 1007, 1014+, 2374 |
| Chemotherapy with CR | 14/15 | 60, 96, 159, 312+, 372+, 438+, 527, 646, 1173, 1245, 1416+, 1453+, 1463+, 1563+ |
| Chemotherapy without CR | 6/22 | 152, 617+, 800, 977, 1234+, 1263+ |
Following allogeneic SCT, 73 patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDSs) in the EBMT-95 cohort were treated with DLT. One group of 36 patients received no chemotherapy prior to DLT; 9 individuals showed complete remissions with survival times beyond 100 days. Following chemotherapy 15 patients entered complete remission; their survival times after DLT revealed a broad time span, with most remissions lasting more than 150 days. Of 22 patients who failed to achieve complete remission with chemotherapy, 6 benefited from DLT, achieving survival times of more than 150 days.